Direct medical cost related to the management of pemphigus: A pilot Tunisian study.
Tunis Med
; 102(2): 74-77, 2024 Feb 05.
Article
em En
| MEDLINE
| ID: mdl-38567471
ABSTRACT
INTRODUCTION:
Pemphigus is a therapeutically challenging disease with high morbidity and economic burden. First-line prescription of rituximab remains limited in Tunisia due to its high cost. Systemic steroids remain the standard of care but are associated with a major risk of morbidities and higher treatment costs.AIM:
To assess the direct medical costs of pemphigus in Tunisia.METHODS:
Retrospective estimation of direct medical costs during the 18 months following the diagnosis using the "bottom-up approach" in the Dermatology Department of Hedi Chaker Hospital, Sfax, Tunisia.RESULTS:
Total medical costs were estimated at 38745.7 , with an average cost of 1 210 per patient and per year paraclinical investigations (46%), medical treatment (30%), hospitalization (21%) and outpatient visits (3%). The average cost was the highest in the age group of 15-24 years (1553 ). Treatment costs related to corticosteroid-induced morbidity were estimated at 1208 .CONCLUSIONS:
The management of pemphigus in Tunisia needs to be adapted to take into account the health economic analysis in order to reduce overall disease costs and the burden of steroid-induced morbidities.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pênfigo
Limite:
Adolescent
/
Adult
/
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article